Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Blood (2023) 142 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2023-182946

Published: 2023

Journal Articles

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Blood (2021) 138 (Supplement 1): 134.

https://doi.org/10.1182/blood-2021-153680

Published: 2021

Journal Articles

Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Blood (2021) 138 (Supplement 1): 384.

https://doi.org/10.1182/blood-2021-153364

Published: 2021

Journal Articles

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Blood (2021) 138 (Supplement 1): 2487.

https://doi.org/10.1182/blood-2021-150337

Published: 2021

Journal Articles

Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2021) 138 (Supplement 1): 48.

https://doi.org/10.1182/blood-2021-148424

Published: 2021

Journal Articles

Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group

Gian Matteo Rigolin, Annamaria Frustaci, Alfonso Piciocchi, MS, Andrea Visentin, MDPhD, Orsola Vitagliano, Marta Coscia, MD PhD, Lucia Farina, Gianluca Gaidano, Roberta Murru, MD, Marzia Varettoni, Luca Arcaini, Francesca Cibien, MD, Rossella Paolini, Paolo Sportoletti, MD, Daniela Pietrasanta, MD, Anna Lia Molinari, MD, Francesca M. Quaglia, Luca Laurenti, MD, Roberto Marasca, MD, Monia Marchetti, MD, Annalisa Chiarenza, MD PhD, Francesca Romana Mauro, MD PhD, Omar Perbellini, Donato Mannina, MD, Rosaria Sancetta, MD, Attilio Olivieri, MD, Stefano Molica, MD, Fabrizio Pane, MD, Caterina Patti, MD, Fiorella Iliariucci, Alessandro Gozzetti, Catello Califano, MD, Piero Galieni, Accursio Fabio Augello, MD, Daniele Vallisa, MD, Francesca Cura, Enrico Crea, Paola Fazi, MD, Giulia Zamprogna, MD, Mauro Krampera, MD PhD, Livio Trentin, MD, Felicetto Ferrara, MD, Massimo Gentile, Marco Montillo, Robin Foà, MD, Antonio Cuneo, MD

Blood (2020) 136 (Supplement 1): 23–25.

https://doi.org/10.1182/blood-2020-134669

Published: 2020

Journal Articles

Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134875

Published: 2020

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi

Blood (2019) 134 (Supplement_1): 398.

https://doi.org/10.1182/blood-2019-123027

Published: 2019

Journal Articles

Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory WaldenstrÃ¶m Macroglobulinemia Patients

Blood (2018) 132 (Supplement 1): 1607.

https://doi.org/10.1182/blood-2018-99-114023

Published: 2018

Journal Articles

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

Blood (2018) 132 (Supplement 1): 401.

https://doi.org/10.1182/blood-2018-99-110289

Published: 2018

Journal Articles

IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)

Blood (2017) 130 (Supplement 1): 1506.

https://doi.org/10.1182/blood.V130.Suppl_1.1506.1506

Published: 2017

Journal Articles

Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Blood (2016) 128 (22): 472.

https://doi.org/10.1182/blood.V128.22.472.472

Published: 2016

Journal Articles

Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi

Blood (2013) 122 (21): 850.

https://doi.org/10.1182/blood.V122.21.850.850

Published: 2013

Journal Articles

Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)

Blood (2012) 120 (21): 903.

https://doi.org/10.1182/blood.V120.21.903.903

Published: 2012

Journal Articles

Long Term Follow up Analysis Following Front Line Therapy with Dexamethasone or Dexamethasone Plus Rituximab in Adults with Primary Immune Thrombocytopenia.

Blood (2009) 114 (22): 2415.

https://doi.org/10.1182/blood.V114.22.2415.2415

Published: 2009

Journal Articles

A Prospective Randomized Study Comparing Rituximab and Dexamethasone Vs Dexamethasone Alone in ITP: Results of Final Analysis and Long Term Follow up

Blood (2008) 112 (11): 1.

https://doi.org/10.1182/blood.V112.11.1.1

Published: 2008

Journal Articles

Role of Anemia in Survival of Elderly Aggressive Non-Hodgkin’s Lymphoma Patients Following Chemotherapy.

Pier Luigi Zinzani, Monica Tani, Anna Lia Molinari, Giuseppe Visani, Patrizia Gentilini, Luciano Guardigni, Vitorio Stefoni, Lapo Alinari, Enrica Marchi, Annalisa Gabriele, Gerardo Musuraca, Maria Paola Fina, Michele Baccarani

Blood (2004) 104 (11): 3315.

https://doi.org/10.1182/blood.V104.11.3315.3315

Published: 2004

NARROW

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Adding Romidepsin to CHOEP in First Line Treatment of Peripheral T-Cell Lymphomas Does Not Improve the Response Rate: Final Analysis of Phase II PTCL13 Study

Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL)

Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group

Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL)

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi

Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory WaldenstrÃ¶m Macroglobulinemia Patients

Lenalidomide Maintenance after Autologous Transplantation Prolongs PFS in Young MCL Patients: Results of the Randomized Phase III MCL 0208 Trial from Fondazione Italiana Linfomi (FIL)

IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)

Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi

Rituximab-CHOP21 Plus Lenalidomide (LR-CHOP21) Is Effective and Feasible in Elderly Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of Phase II REAL07 Study of the Fondazione Italiana Linfomi (FIL)

Long Term Follow up Analysis Following Front Line Therapy with Dexamethasone or Dexamethasone Plus Rituximab in Adults with Primary Immune Thrombocytopenia.

A Prospective Randomized Study Comparing Rituximab and Dexamethasone Vs Dexamethasone Alone in ITP: Results of Final Analysis and Long Term Follow up

Role of Anemia in Survival of Elderly Aggressive Non-Hodgkin’s Lymphoma Patients Following Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only